2269: Future Recovery And New Modalities Will Drive Balanced Opportunities And Risks

Analysts have raised their price target for WuXi Biologics (Cayman) from HK$38.19 to HK$38.61. They cite improved profit margins and revenue growth expectations, along with optimism for recovery and long-term growth opportunities.

Analysts have modestly raised their price target for WuXi Biologics (Cayman) from HK$38.12 to HK$38.19, citing improving first-half performance and expected long-term growth from new modalities as key factors for the upgrade. Analyst Commentary Recent street research reflects cautiously optimistic sentiment toward WuXi Biologics (Cayman), with revised recommendations and higher price targets indicating improved confidence in the company's prospects.

WuXi Biologics (Cayman) received a higher analyst price target, rising from HK$37.16 to HK$38.12. Analysts point to a preliminary first half recovery and optimism about new modalities supporting future growth.

The increase in WuXi Biologics (Cayman)’s consensus price target reflects improved market sentiment driven by a higher future P/E and a slight uptick in net profit margin, raising the fair value estimate from HK$33.29 to HK$34.82. What's in the News Dundalk, Ireland facility approved by EMA as a commercial manufacturing site, marking first commercial biologic launch from WuXi Biologics' Ireland site and reinforcing its global regulatory compliance with a 100% inspection success rate.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has increased revenue growth from 13.5% to 15.0% and increased future PE multiple from 19.4x to 22.4x.

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.

AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.